L26/P-743 Relative biopotency differences between follitropin delta and follitropin alfa: a pooled analysis of randomized controlled trials comparing gonadotropin consumption per oocyte retrieved
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1070 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von E. Gravotta und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Study question What is the relative biopotency of follitropin delta, across individualized and conventional dosing regimens, compared with follitropin alfa, measured by gonadotropin consumption per oocyte retrieved? Summary answer Follitropin delta demonstrated higher relative biopotency than follitropin alfa, with lower gonadotropin consumption per oocyte retrieved across both dosing strategies and similar first-transfer pregnancy rates. What is known already Follitropin delta, algorithmically dosed based on anti-Müllerian hormone (AMH) and bodyweight, has demonstrated efficacy comparable to conventionally dosed follitropin alfa (150 IU/day starting dose, thereafter dose adjustments allowed), with a favourable safety profile. Previous analysis of > 1500 clinical trial participants established that follitropin delta 10 μg provides an ovarian response similar to follitropin alfa 150 IU (11 μg)/day. Additional RCTs showed that conventional follitropin delta (10 or 15 µg/day) provides similar oocytes yields to follitropin alfa (150 or 225 IU/day). However, a comparison of gonadotropin consumption per oocyte retrieved across dosing strategies has not been performed to quantify relative biopotency. Study design, size, duration Two pooled RCT datasets compared follitropin delta with follitropin alfa: (1) individualized follitropin delta (algorithm-based) versus conventional follitropin alfa (150 IU/day starting dose), and (2) conventional follitropin delta (10 or 15 µg/day) versus conventional follitropin alfa (150 or 225 IU/day starting dose). Relative potency was defined as number of oocytes retrieved per unit dose of gonadotropin. Mean total dose per oocyte retrieved, and pregnancy rates, risk differences and confidence intervals (CIs) were calculated. Participants/materials, setting, methods Women, 18–40 years, BMI 17.5–32 kg/m2, with either infertility or an infertile male partner, eligible for IVF/ICSI, were enrolled at reproductive clinics predominantly in Europe and Asia. Oocyte counts were modelled using negative binomial regression with a log link, gonadotropin total dose as a log offset, and covariates; relative biopotency was estimated as the adjusted oocyte yield per unit dose. Pregnancy outcomes were analysed using logistic regression and the Cochran-Mantel-Haenszel method. Main results and the role of chance Overall, 2954 participants were recruited (Oct-2013 to May-2025): 1669 and 1285 women received individualized (algorithm-based dosing) follitropin delta or conventional follitropin alfa, and 348 and 253 women received conventional follitropin delta and follitropin alfa, respectively. Baseline characteristics and infertility history were balanced between comparator groups in each dataset. Mean gonadotropin dose per oocyte retrieved was 8.6 µg/oocyte for individualized follitropin delta versus 10.3 µg/oocyte for follitropin alfa, and 13.0 µg/oocyte for conventionally dosed follitropin delta versus 14.7 µg/oocyte for follitropin alfa. Modelled relative biopotency for follitropin delta (individualized or conventional) versus follitropin alfa was 1.20 (95% CI 1.14, 1.26; p < 0.0001) and 1.13 (95% CI 1.04, 1.23; p = 0.0027), respectively, indicating a consistently higher ovarian response per unit dose with follitropin delta across dosing strategies. Clinical pregnancy rates from first transfer were 34.4% (95% CI 32.0–36.8%) with individualized follitropin delta versus 32.6% (95% CI 30.0–35.4%) with follitropin alfa (p = 0.3542; RD 1.7% [95% CI –1.9, 5.4%]), and 29.7% (95% CI 24.9, 34.9%) with conventional follitropin delta versus 26.4% (95% CI 21.2, 32.5%) with follitropin alfa (p = 0.4062; risk difference 2.9% [95% CI –4.4, 10.2]). Limitations, reasons for caution Direct comparisons between the two pooled analyses should be made with caution due to differences between trial populations (i.e., trials with the higher fixed gonadotrophin starting doses excluded potential high responders). The trials included in the pooled analyses were not originally designed to compare biopotency of the gonadotropins. Wider implications of the findings These analyses support higher relative biopotency of follitropin delta compared with follitropin alfa, with consistently lower mean gonadotropin consumption per oocyte across both individualized and conventional dosing regimens. Pregnancy rates from first transfer were similar for both gonadotropins. These data may inform dose selection and pharmacoeconomic considerations in clinical practice. Trial registration number Yes
Zitieren
APA
Gravotta, E., García-Velasco, J., Nelson, S., Bagci, E. B., Falahati, A., Griesinger, G., Polyzos, N., & Lobo, R. (2026). L26/P-743 Relative biopotency differences between follitropin delta and follitropin alfa: a pooled analysis of randomized controlled trials comparing gonadotropin consumption per oocyte retrieved. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1070
Vancouver
Gravotta E, García-Velasco J, Nelson S, Bagci EB, Falahati A, Griesinger G, et al. L26/P-743 Relative biopotency differences between follitropin delta and follitropin alfa: a pooled analysis of randomized controlled trials comparing gonadotropin consumption per oocyte retrieved. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1070
BibTeX
@article{Gravotta2026,
author = {Gravotta, E. and García-Velasco, J. and Nelson, S. and Bagci, E. Bakhtadze and Falahati, A. and Griesinger, G. and Polyzos, N.P. and Lobo, R.},
title = {L26/P-743 Relative biopotency differences between follitropin delta and follitropin alfa: a pooled analysis of randomized controlled trials comparing gonadotropin consumption per oocyte retrieved},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1070}
}
EUVIMED